Reslizumab (Cinqair) — CPB 0907 | AETNA Coverage Update

Aetna modified CPB 0907 for reslizumab (Cinqair), effective January 5, 2026. Here's what billing teams need to know before submitting claims under HCPCS J2786.

Aetna, a CVS Health company, updated its Clinical Policy Bulletin 0907 governing reslizumab (Cinqair) coverage for commercial medical plans. The revised coverage policy adds a new fast-track approval path for members who've previously used a biologic for asthma, tightens the step therapy framework for new starts, and retains strict prior authorization requirements. Your claims under J2786, billed alongside infusion codes 96365 and 96366, live or die on documentation that maps to these exact criteria.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Reslizumab (Cinqair) — CPB 0907
Policy Code	CPB 0907
Change Type	Modified
Effective Date	January 5, 2026
Impact Level	High
Specialties Affected	Allergy/Immunology, Pulmonology
Key Action	Update precertification documentation to reflect eosinophil counts, biologic history, and current controller regimen before submitting J2786 claims

---

Aetna Reslizumab Coverage Criteria and Medical Necessity Requirements 2026

The revised CPB 0907 Aetna coverage policy creates two distinct paths to initial approval. Understanding which path applies to your patient determines what documentation you need — and missing the wrong box will produce a claim denial fast.

Path 1 — Prior Biologic Use:
If a member received any biologic drug indicated for asthma (such as Dupixent or Nucala) within the past year, Aetna considers reslizumab medically necessary. This is a shorter checklist. Document the prior biologic, the dates of administration, and the asthma diagnosis. That's your approval path.

Path 2 — Severe Asthma with Full Criteria:
For members without recent biologic history, all of the following must be true:

The real issue here is documentation specificity. "Uncontrolled asthma" is not enough. You need the eosinophil count on paper, the controller medications with doses, and a dated record of at least one qualifying exacerbation. Aetna's prior authorization reviewers will check each box.

Prescriber Requirement:
Reslizumab must be prescribed by — or in consultation with — an allergist/immunologist or pulmonologist. Claims from a PCP without that consultation note will not survive review.

Precertification:
All Aetna participating providers must precertify reslizumab before administration. Call (866) 752-7021 or fax (888) 267-3277. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal. Do not schedule the infusion before you have the auth in hand.

Site of Care:
Aetna's Site of Care Utilization Management Policy applies to reslizumab. This is the same pattern you've seen on other specialty drug infusions — Aetna may redirect members to lower-cost infusion settings. Check the site of service policy before you assume your facility is approved for reimbursement.

---

Continuation of Therapy — What Aetna Requires to Keep Coverage

Continuation of reslizumab billing isn't automatic. Aetna requires a separate showing of medical necessity at each continuation request.

All three of these must be true for continuation approval:

1. Member is 18 or older
2. Asthma control has improved — shown by reduced frequency or severity of symptoms and exacerbations, or a reduction in daily oral corticosteroid dose
3. Member continues using both a high-dose inhaled corticosteroid and an additional controller alongside reslizumab

Build your continuation documentation before the auth expires. A reduction in exacerbation frequency is objective. A reduction in oral corticosteroid dose is even cleaner — get the before and after doses in the chart.

---

Aetna Reslizumab Exclusions and Non-Covered Indications

Aetna treats all indications outside severe asthma as experimental, investigational, or unproven. There is no off-label pathway under this coverage policy.

The combination restriction is the other big denial risk. A member cannot use reslizumab (J2786) at the same time as any other biologic or targeted synthetic drug for asthma. That means J2182 (mepolizumab), J2356 (tezepelumab-ekko), and J2357 (omalizumab) are explicitly blocked from concurrent billing. If your patient is transitioning off another biologic, document the discontinuation date before you submit the reslizumab prior auth.

The policy also flags current smokers and vapers — your team should ensure smoking cessation counseling (CPT 99406 or 99407) is offered and documented. This is a clinical note requirement, not a coverage blocker, but it may come up in audits.

---

Coverage Indications at a Glance

---

Aetna Reslizumab Billing Guidelines and Action Items 2026

These steps apply starting January 5, 2026. If you're submitting J2786 claims under Aetna commercial plans, work through this list now.

Copy Action Items

If your payer mix includes a high volume of Aetna commercial asthma patients and you're uncertain how the biologic history pathway interacts with your current prior auth process, loop in your compliance officer or billing consultant before January 5, 2026.

---

CPT, HCPCS, and ICD-10 Codes for Reslizumab Under CPB 0907

Covered HCPCS Code (When Selection Criteria Are Met)

Code	Type	Description Copy
J2786	HCPCS	Injection, reslizumab, 1 mg

CPT Codes Related to Reslizumab Administration and Counseling

HCPCS Codes Not Covered in Combination with Reslizumab

Code	Type	Description	Reason Copy
J2182	HCPCS	Injection, mepolizumab, 1 mg	Not covered in combination with reslizumab
J2356	HCPCS	Injection, tezepelumab-ekko, 1 mg	Not covered in combination with reslizumab
J2357	HCPCS	Injection, omalizumab, 5 mg	Not covered in combination with reslizumab

Key ICD-10-CM Diagnosis Codes

The full policy lists 153 ICD-10-CM codes. The complete code set is available at the full CPB 0907 policy record.

---